Our Science
Our Story
News
Connect
Globe Newswire
August 1, 2024
Featured article
Read More
March 21, 2021
In The News
Endpoints News
A pair of Lyell founders look to shift the cell therapy paradigm — and they've got $30M to get their plan off the ground
READ MORE
DOWNLOAD
1
All
PR
Publications
October 9, 2023
Cancer Cell
Building smart CAR T cell therapies: The path to overcome current challenges
August 2, 2023
GeekWire
Seattle startups move into growing science cluster in South Lake Union
August 1, 2023
American Society for Gene & Cell Therapy (ASGCT)
OutSmart™ IL-2/15 Safely Stimulates CAR T Proliferation and Persistence in the Tumor while Limiting Regulatory T Cell Activation
July 10, 2023
How AI is changing the way scientists engineer drugs, biosensors, enzymes and more
May 26, 2023
Outpace Bio expands cell therapy R&D, nets research collaborations in Seattle
May 22, 2023
Public Relations
Outpace Bio expands Seattle presence with cell therapy research hub & collaborations with leading experts in protein design & cancer immunotherapy
November 5, 2024
Outpace Bio to present new data on programmed CAR T cell candidate OPB-101 at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development
April 4, 2024
Outpace Bio Announces Multiple Presentations at the 2024 American Association of Cancer Research (AACR) Annual Meeting
October 31, 2023
Outpace Bio to present new data on tumor-restricted IL-12 designed leveraging OutSmart technology to enhance solid tumor T cell therapies at SITC 2023
May 18, 2023
Outpace Bio to present new data on OutSmart™ IL-2/15, a CAR T cell-produced designed cytokine with tumor-localized immune cell activity, at the 2023 annual meeting of the American Society of Gene & Cell Therapy (ASGCT)
November 19, 2024
Society for Immunotherapy of Cancer (SITC)
April 7, 2024
American Association for Cancer Research (AACR)
In vitro modeling of antigen-driven exhaustion in human CAR T cells
"Development of tumor-restricted IL-12 with antigen-dependent expression and localized IL-12 activity"
OPB-101: An optimized mesothelin-specific CAR T cell product expressing CD8-targeted IL-2/15 and engineered to resist T cell exhaustion
November 3, 2023
Protein design and inducible expression allow context-dependent, localized IL-12 activity to enhance solid tumor T cell therapies
The Outpace Press Kit is designed to help journalists research Outpace. Please contact our communications team if you need more information or to schedule an interview.